Beauty & Style

Presently, over 150 neoantigen targeted therapies are now being evaluated for advanced cancer indication

Using neoantigens in therapy has shown the opportunity to elicit a powerful T cell mediated immune response. Several therapy candidates are now being investigated both as monotherapies and in conjunction with various immune checkpoint inhibitors, for example atezolizumab, durvalumab, ipilimumab, and nivolumab. Of those, certain pipeline candidates have previously joined mid to late-stage (phase II and above) trials and therefore are expected to go into the market within the next 5-ten years.

To buy this 320  page report, featuring 110  figures and 140  tables, check out here

The USD 3 billion (by 2030) financial chance inside the neoantigens market continues to be examined over the following segments:

•           Type of target disease indication

•           Bone cancer

•           Colorectal cancer

•           Gynecological cancer

•           Non-small cell cancer of the lung

•           Renal cell carcinoma

•           Other cancers

•           Type of neoantigens

•           Personalized neoantigens

•           Off-the-shelf neoantigens

•           Type of immunotherapy

•           Dendritic cell vaccines

•           DNA / RNA-based vaccines

•           Protein / peptide-based vaccines

•           TIL-based therapies

•           Route of administration

•           Intradermal

•           Intravenous

•           Subcutaneous

•           Other routes

•           Key geographical regions

•           North America

•           Europe

•           Rest around the globe

The report features inputs from eminent industry stakeholders, based on whom neoantigen targeted therapies are anticipated is the newest part of cancer immunotherapy. Much like Vehicle-T cell therapies, these therapies have, to date, shown significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held using the following experts:

•           Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)

•           Ella Sorani (V . P . Development and research, BioLineRx)

•           Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

The Neoantigen Targeted Therapies, 2019-2030 report features the next companies, which we identified to become key players within this domain:

•           Bavarian Nordic

•           Genocea Biosciences

Pr Release: Variation 3 (Format 4)

•           Gradalis

•           Immunicum

•           Immunovative Therapies

•           Iovance Biotherapeutics

•           Medigene

•           Neon Therapeutics

•           Precision Biologics

•           Vaxon Biotech

Table of Contents


2. Executive Summary



1.Market Overview

2.Company Profiles: Neoantigen Targeted Therapies

3.Publication Analysis

4.Patent Analysis

5.Partnerships and Collaborations

6.Funding and Investment Analysis

7.Market Forecast and Chance Analysis

8.Concluding Remarks

9.Executive Insights

10.Appendix 1: Tabulated Data

11.Appendix 2: Listing of Organizations and companies